Table 1.
List of vaccines under clinical testing without specific vaccine adjuvants.
| Malaria Vaccine | Clinical Trial Identifier | Current Stage |
|---|---|---|
| ChAd63 RH5 (chimpanzee adenovirus serotype 63 reticulocyte-binding protein homolog 5) | NCT02181088 | Phase 1 |
| MVA (modified vaccinia virus Ankara) RH5 | NCT02181088 | Phase 1 |
| PEBS-POC1 (synthetic protein containing 131 amino acids) | NCT01605786 | Phase 1 |
| ChAd63-METRAP (multiple epitope string and thrombospondin-related adhesion protein) | NCT03084289 | Phase 1 |
| MVA METRAP | NCT03084289 | Phase 1 |
| DNA-Ad (contains a combination of circumsporozoite (CS) protein and AMA1) | NCT00870987 | Phase 2 |
| PfSPZ (P. falciparum (Pf) sporozoite (SPZ)) | NCT02601716 | Phase 2 |
| Ad35.CS.01 (P. falciparum CS surface antigen is inserted in a replication deficient Adenovirus 35 backbone) | NCT01018459 | Phase 1 |
| CS protein expressed either in MVA, or an attenuated Fowl pox virus strain (FP9). | NCT00121771 | Phase 1 |
| AdCh63-MSP1 (merozoite surface protein-1) and MVA-MSP1 | NCT01003314 | Phase 2 |
| GMZ2 (recombinant hybrid of the glutamate rich protein (GLURP) and the merozoite surface protein 3 (MSP 3)) | NCT00424944 | Phase 1 |
| FP9-PP and MVA-PP (FP9 polyprotein, modified virus Ankara polyprotein) | NCT00374998 | Phase 1 |
| p52-p36-GAP (genetically attenuated parasite malaria vaccine) | NCT01024686 | Phase 2 |
| PfSPZ-GA1 (genetically attenuated PfSPZ) | NCT03163121 | Phase 1 |
| ChAdOx1 LS2 (malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain) and MVA LS2 | NCT03203421 | Phase 2/Phase 1 |
| DNA-Ad (it contains a liver-stage antigen (circumsporozoite protein) and an antigen (apical membrane antigen 1)) | NCT00870987 | Phase 1 |
| NMRC-M3V-Ad-PfCA (NMRC + multi-antigen multi-stage, malaria vaccine + adenovectored + P. falciparum CSP and AMA1 antigens), is a combination of two recombinant adenovirus-derived constructs (adenovectors) | NCT00392015 | Phase 1 |